BioAtla, Inc. (NASDAQ:BCAB) Receives Average Recommendation of “Hold” from Analysts

by · The Cerbat Gem

BioAtla, Inc. (NASDAQ:BCAB – Get Free Report) has been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $4.00.

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a report on Friday. Rodman & Renshaw started coverage on BioAtla in a report on Tuesday. They issued a “buy” rating and a $4.00 price objective for the company.

Read Our Latest Report on BioAtla

BioAtla Trading Down 2.1%

Shares of BioAtla stock traded down $0.01 during trading on Tuesday, reaching $0.31. The stock had a trading volume of 4,455,774 shares, compared to its average volume of 2,532,207. The company has a market capitalization of $18.12 million, a price-to-earnings ratio of -0.27 and a beta of 1.04. The stock has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.61. BioAtla has a 52 week low of $0.24 and a 52 week high of $1.43.

BioAtla (NASDAQ:BCAB – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts forecast that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Trading of BioAtla

A number of large investors have recently added to or reduced their stakes in the company. Sheets Smith Investment Management acquired a new position in BioAtla during the third quarter valued at approximately $46,000. Woodline Partners LP bought a new position in shares of BioAtla in the 1st quarter valued at $26,000. Susquehanna International Group LLP raised its holdings in shares of BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after buying an additional 177,760 shares in the last quarter. Millennium Management LLC bought a new stake in shares of BioAtla during the 3rd quarter worth $235,000. Finally, Acadian Asset Management LLC lifted its position in shares of BioAtla by 968.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after buying an additional 1,531,994 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

(Get Free Report)

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.

Featured Stories